Xcellerant Ventures Ends First Year with 10th Investment, Leading CRISPR QC’s $10 Million Series A Round
By providing a way to standardize measurements for efficiency and accuracy, CRISPR QC enables pharmaceutical and agriculture companies to quickly screen for the best therapeutics to develop into next generation personalized medicines.
- By providing a way to standardize measurements for efficiency and accuracy, CRISPR QC enables pharmaceutical and agriculture companies to quickly screen for the best therapeutics to develop into next generation personalized medicines.
- Chris Yoo, Ph.D., GP of Xcellerant Ventures, says “With CRISPR-based gene editing, we are at the beginning of a truly precise way to treat and cure thousands of genetically-driven diseases.
- Xcellerant Ventures is a leader in investing in startups that can combine technological advances across industries into solutions that make healthcare more precise, more affordable, and more accessible.
- It was instantly clear to us that Xcellerant Ventures was the investor and partner we have been searching for, and we are excited and honored to have Xcellerant lead our Series A."